Advertisement
UK markets open in 4 hours 34 minutes

  • NIKKEI 225

    37,796.28
    -663.80 (-1.73%)
     

  • HANG SENG

    17,295.27
    +94.00 (+0.55%)
     

  • CRUDE OIL

    82.70
    -0.11 (-0.13%)
     

  • GOLD FUTURES

    2,331.10
    -7.30 (-0.31%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,531.22
    -1,951.41 (-3.65%)
     

  • CMC Crypto 200

    1,387.92
    -36.18 (-2.54%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Dr Reddy's falls on concerns Q3 results may miss estimates

Reuters
A medical representative (C) with Abbott talks to a chemist at a market in Pune August 27, 2012. REUTERS/Danish Siddiqui/Files

Reuters Market Eye - Shares in Dr Reddy's Laboratories(NSI:DRREDDY.NS - News) fall 2.1 percent on worries the drug maker will post lower-than-expected October-December earnings, due later in the day.

Margins are also expected to see significant erosion, several dealers add.

Dr Reddy's could miss consensus earnings per share (EPS) estimates by 6 percent in the October-December quarter, according to Thomson Reuters StarMine SmartEstimate data, which measures the forecasts from top-ranked analysts against wider forecasts. * StarMine SmartEstimate suggests EPS for the quarter ending December at 26.03 rupees compared with mean estimate of 27.89 rupees.

(Reporting by Abhishek Vishnoi)